Pliant Therapeutics (NASDAQ:PLRX) stock jumped 28% on Thursday after the company issued an update for a Phase 2b clinical ...

Pliant Therapeutics said Sunday that an experimental pill significantly improved lung function in patients with idiopathic pulmonary fibrosis, or IPF, a deadly lung disease with few approved ...

Pliant Therapeutics has discontinued a phase 2b/3 trial after recording at least a 7% higher rate of adverse events tied to idiopathic pulmonary fibrosis (IPF) in the treatment arms compared to ...

A clinical study testing a Pliant Therapeutics drug once considered a promising prospect for treating a fatal lung disorder is now on pause at the recommendation of independent outside observers.

Pliant plans to assess the full trial data and may explore lower doses in future Phase 2b studies. Ready to turn the market’s comeback into steady cash flow? Grab the top 3 stocks to buy right here.

Pliant Therapeutics (NASDAQ:PLRX) stock plunged 61% in the wake of news that it has paused enrollment in a Phase 2b study of its drug bexotegrast in patients with idiopathic pulmonary fibrosis ...

Pliant Therapeutics announces a workforce reduction and cost-saving measures to extend its cash runway for late-stage clinical trials. Pliant Therapeutics, Inc. has announced a significant ...

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel ...

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial. Pliant Therapeutics ends its Phase 2b IPF trial ...